This retrospective study reviews the results of our experience with the occurrence of CMV DNAemia in islet cell transplanted cynomolgus monkeys subjected to different immunosuppressive protocols, including induction treatment with thymoglobulin (TMG), with a combination of thymoglobulin and fludarabine (FLUD), with cyclophosphamide, or with daclizumab. CMV DNA in the peripheral blood (CMV DNAemia) of 47 monkeys was quantified by real-time PCR on a weekly to biweekly basis. As compared to other immunosuppressive regimens, and in association with greater decreases in WBC, lymphocyte, CD3 + CD4 + , and CD3
INTRODUCTION
currence and severity of CMV infection depend on the type of transplant, the immunosuppressive regimen, and CMV serostatus of the donor and recipient. Clinical Cytomegalovirus (CMV) is a member of the beta class of herpesviruses and is found in humans, nonhumanifestations of CMV can vary from completely asymptomatic infection, defined by active CMV replicaman primates (NHP), and other mammals (5, 11) . It is easily transmitted through contact with body fluids tion in blood in the absence of clinical symptoms or abnormalities in organ function, to fulminant CMV dis- (2, 5, 11, 33, 57) , infecting individuals early in life and remaining latent thereafter (5, 11) . Primary infection in imease, characterized by CMV infection with overt clinical symptoms or organ dysfunction (38). Incidence of CMV munocompetent individuals is usually benign, and does not result in clinical signs of disease (3, 5) . However, in infection in humans has been reported in solid organ (9, 13, 39) , bone marrow (14,43), islet after kidney, siimmunocompromised individuals, such as in immunosuppressed transplant recipients, CMV infection can multaneous islet with kidney (17,58), and islet alone transplantation (IAT) (16) . The incidence of CMV seroproduce life-threatening complications (20, 31) . The oc-conversion and transmission in IAT is low, with few Islet Isolation and Transplantation cases of diseases reported to date (6, 16, 19, 24, 49, 59 ).
Islets were isolated from the donor pancreas using a Nonhuman primates (NHP) and humans share close modification of the automated digestion-filtration method developmental and evolutionary relationships. Results for human islet isolation (37, 46) followed by density from NHP models can provide invaluable aid to accelergradient purification in a COBE 2991 centrifuge (COBE, ate the clinical development of promising new therapies Lakewood, CO). for treating human disease. There are many similarities Recipients were rendered diabetic by streptozotocin in the nature, history, and course of simian and human administration (10) and received an intrahepatic islet cell CMV infections (5) . CMV infection was reported in the infusion [4, [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ,400 islet equivalent (IEQ)/kg body first week posttransplantation in cynomolgus monkeys weight] under general anesthesia on postoperative day (Macaca fascicularis) receiving kidney transplants along (POD) zero. with humanized MHC class II-specific monoclonal antiImmunosuppression body CDP855 (35) . Detectable CMV viral load in blood by PCR assay (1) and CMV disease was reported (44) in Table 1 summarizes the various experimental protorhesus monkey recipients of islet cell or renal allografts cols and immunosuppressive regimens used to treat the treated with anti-CD40 monoclonal antibody. CMV animals. All animals received daily intramuscular (IM) DNAemia was found in immunosuppressed baboons sirolimus (LC Laboratories, Woburn, MA) to achieve (40) and cynomolgus (29) and rhesus (12) monkeys in and maintain trough levels between 12 and 20 ng/ml. pig-to-primate models of xenotransplantation.
Samarium-Lexidronam (Sm-Lex) Protocol. Fifteen We have utilized a number of different agents in animals were administered 153 Samarium-Lexidronam allogeneic islet and islet/bone marrow transplant stud-(Quadramet, Berlex Laboratories, Wayne, NJ) intraveies in a cynomolgus monkey model. Sirolimus (Rapanously (IV) at 3 mCi/kg on days 12-14 before islet mune), tacrolimus (Prograf), and daclizumab (Zenatransplantation. Among the 15 monkeys, five groups pax), as well as thymoglobulin (26, 27) , the lymphocyte were divided based on the immunosuppressive induction immunosuppressive agent, fludarabine (7, 23, 53, 56) , treatment received as described in detail in Table 1  and 153 Samarium-EDTMP, a bone-seeking radioactive (groups 1-5). All 15 monkeys received either single or compound (22, 34, 55) have been employed in various multiple doses of donor bone marrow infusions between combinations. The present study is a retrospective analPODs −1 and 28. One animal received anti-CD40L ysis of the frequency, severity, and duration of CMV monoclonal antibody (murine 5c8 clone). viral load in cynomolgus monkey recipients of islet alAnti-CD40L Protocol. Eight monkeys were adminislografts treated with various immunosuppressive regitered IV anti-CD40L specific monoclonal antibody mens that differentially affect white blood cells (WBC) (IDEC 131, Biogen IDEC, Boston, MA) at 20 mg/kg on and T-cell levels.
PODs −1, 0, 3, 10, 18, 28 and every 28 days for 6 months (groups 6-7, Table 1 ). Five of eight also re-MATERIALS AND METHODS ceived thymoglobulin at 10 mg/kg and fludarabine at 50 Cynomolgus Monkeys mg/m 2 on PODs −5, −4, −3, and −2 (group 6, Table 1 ). All eight monkeys were given at least one dose of donor Donor and recipient cynomolgus monkeys (Macaca bone marrow infusion between PODs −1 and 28. fascicularis) were obtained from Charles River BRF, Thymoglobulin and Fludarabine Protocol. Six monInc. (Houston, TX) or from The Mannheimer Foundakeys received thymoglobulin at 10 mg/kg and fludaration, Inc. (Homestead, FL). All animals were negative bine at 50 mg/m 2 on PODs −5, −4, −3, and −2; and 2-3 for tuberculosis, herpes B, SRV, SIV, and STLV-1 and doses of donor bone marrow infusion between POD −1 were negative for CMV DNA by quantitative PCR. Reand 11 (group 8, Table 1 ). cipients were 3-6 years old and weighed between 2.8 and 5.3 kg at the time of islet transplantation. Donors
Marginal Mass Protocol. Eighteen monkeys participated in a marginal mass model protocol in which islets were 4-12 years old and weighed between 3.7 and 12 kg. Donor-recipient pairs were ABO compatible (41) .
isolated from one or a pool of two donors were infused into two metabolically closely matched recipients at a We followed CMV DNA levels posttransplant in 47 recipients.
dose of 5,000 IEQ/kg (10) . One of the paired recipients received an agent designed to limit early islet loss or Monkeys were single housed, supplied with water ad libitum, and fed twice daily. All study protocols were enhance engraftment, including inhibitors of coagulation, growth factors, or inhibitors of inflammation approved by The Institutional Animal Care and Use Committee of The University of Miami.
(group 9, Table 1 ). The matched recipients were used as With the exception of groups 9 and 10, all animals received at least one donor bone marrow infusion between POD −1 and 28. *Controls. †Animals received oral valganciclovir starting POD −14 to −7 twice a day (20 mg/kg marked as XX, or 10 mg/kg marked as X). ‡CMV DNAemia was defined as detection of CMV DNA loads of more than 0.1 copies/ng DNA in a sample.
controls (group 10, Table 1 ). This protocol included a positive for CMV DNA by PCR. When animals had CMV levels over 10 copies/ng DNA, IV ganciclovir (10 steroid-free immunosuppression, consisting of IV daclizumab induction (five doses at 1 mg/kg starting POD mg/kg; Cytovene, Roche) was given for a course of 7 days followed by oral valganciclovir at 20 mg/kg twice −1 every 2 weeks), daily IM tacrolimus (Astellas Pharma US, Inc., Deerfield, IL; trough levels of 4-6 ng/ml), and daily. daily IM sirolimus (trough levels of 12-20 ng/ml) start-CMV Monitoring ing POD −2 or −1.
CMV DNA was quantitated in peripheral blood by CMV Prophylaxis and Treatment using real-time PCR (LightCycler, Roche) with the primers and probe described by Kaur et al. (36) . DNA Except for the animals in groups 7, 9, and 10, all other animals received prophylaxis treatment for CMV was extracted from EDTA-anticoagulated blood by using "QIAamp DNA Blood Mini" kit (Qiagen, Inc., Vaby giving valganciclovir (Roche) in a Fig Newton cookie (Kraft Foods, Inc.) starting on POD −14 to −7.
lencia, CA). Amplification of each sample was performed in a 20-µl mixture containing 1× LightCycler Animals in groups 1, 4, 5, 6, 8, and 2/9 in group 9 received 20 mg/kg, twice a day (n = 22), and animals in FastStart DNA Master Hybridization Probe (Roche), 4 mM MgCl 2 , 0.5 µM of each primer, 1 µM TaqMan groups 2 and 3 received 10 mg/kg, twice a day (n = 6). Seven of nine animals in group 9 and all animals in Probe, and 50 ng genomic DNA. PCR amplification consisted of 95°C for 10 min, followed by 40 cycles of groups 7 and 10 (n = 19) received valganciclovir treatment only when a posttransplant blood sample tested denaturation at 95°C for 15 s, and annealing and/or extension for 1 min at 60°C. Serial 10-fold dilutions of sion, manual forward selection of descriptors has been performed until no more descriptors with statistically CMV DNA fragment (copy number 10 7 -10 1 ) were included in every PCR run for the construction of the stansignificant contributions could be found. Because intercepts were not significantly different from zero (p = dard curve for quantitation of CMV DNA in the samples. CMV results were expressed as CMV copies/ng 0.47), a zero intercept was enforced in all cases; this considerably improved all correlations, and it is in line DNA. Each sample was analyzed in duplicate and β-actin amplification was used to ensure the quality of with the assumption that DNAemia is present mainly because of the immunosuppressive regimen. Statistical each sample (25) .
All animals underwent CMV testing weekly for the analyses were performed using SPSS 12.0 (SPSS, Inc., Chicago, IL) and MS Excel 2007 (Microsoft, Seattle, first month posttransplant and biweekly thereafter. CMV DNAemia was defined as the detection of a CMV DNA WA). load of more than 0.1 copies/ng DNA in a sample. If RESULTS CMV DNAemia was detected in any animal, weekly samples were tested until CMV DNAemia was cleared.
CMV DNAemia was detected in the peripheral blood Various tissues were collected at the time of animal necof 27/47 or 57.4% of the monkeys studies ( Table 1 of time ranging from 7 to 210 days; the rest of the 11 animals had one positive sample point and went back to Immunophenotyping negative status within 7 days, once (n = 5/11) or multiCell surface antigens on whole blood were analyzed ple times (n = 6/11). The frequency, intensity, and durausing a Coulter Epics XL flow cytometry (Beckman tion of CMV viral load were affected by the choices of Coulter) (48) . Briefly, 100 µl of EDTA-anticoagulated immunosuppressive treatment as discussed below. blood was stained with the following monoclonal antiImmunosuppression and CMV DNAemia bodies (mAbs): anti-CD3 FITC (clone SP34; BD Pharmingen, San Diego, CA), anti-CD4 PE (clone MT477;
Thymoglobulin and Fludarabine Are Associated With BD Pharmingen), anti-CD8 PC5 (clone B911; Beckman an Increased Risk of CMV DNAemia in Islet Cell TransCoulter, Fullerton, CA), and anti-CD20 ECD (clone planted Monkeys. The incidence of CMV DNAemia in B9E9; Beckman Coulter), and the appropriate isotypic animals that received thymoglobulin induction therapy controls. Erythrocytes were lysed using an ImmunoPrep with or without fludarabine was significantly higher Reagent System and a Q-Prep Workstation (Beckman (p < 0.01) compared to that seen in animals that reCoulter). Lymphocytes were gated on the forward and ceived other treatments (Table 1 , Fig. 1A , B). The highside scatter pattern and 10,000 events were collected. est incidence of CMV DNAemia was observed in aniData are represented as an absolute count (cells/µl). mals treated with both thymoglobulin and fludarabine (100%, groups 3, 4, and 6; Table 1 , Fig. 1A ,
B). MonStatistics and Data Analysis
keys that received thymoglobulin without fludarabine All values <0.1 copies/ng DNA limit have been con-(group 2, Table 1 ) also had a higher incidence of CMV sidered as 0 (no DNAemia) for the quantitative analysis.
DNAemia (3/4, 75%) compared to those that did not Duration was calculated as the longest continuous period receive thymoglobulin (p < 0.05). of consecutive positive DNAemia observations. ComCyclophosphamide. Induction treatment with cycloparisons of CMV DNAemia among different treatment phosphamide alone had no significant impact on the ocgroups were carried out by linear mixed models or twocurrence of CMV DNAemia. Four animals received cysample t-tests (assuming equal variances) with α = 0.05.
clophosphamide only as an induction treatment in the As a composite measure of severity and duration, an Sm-Lex protocol (group 1, Table 1 ), and only 1/4 aniarea under the curve (AUC) type descriptor has been mals experienced a weak "one-point-CMV DNAemia" calculated using the linear trapezoidal rule. The multiple throughout the posttransplant monitoring period. linear regression type analysis has been performed using indicator variables (I) for the presence (I = 1) or absence
Steroid-Free Immune Suppression (SFIS) (Marginal Mass Protocol).
Animals that received SFIS were found (I = 0) of each medication using all available data (n = 706) for the CMV DNAemia intensity. Because of the to develop CMV DNAemia less frequently: in a total of 18 animals, only 33% of group 9 (3/9) and 44% of group wide-ranging distribution of variables, log-transformed data were used as customary to better normalize distri-10 (4/9) had measurable CMV virus (Table 1, Fig. 1A ), a marked contrast with recipients of thymoglobulin ± bution, and a log e (y + 1) type transformation was employ when 0 values were present (50, 54) . For the regresfludarabine (p < 0.001). Furthermore, there was no dif- ference in CMV DNAemia between "controls" and the In an attempt to quantitatively assess the relative contribution of each treatment to CMV DNAemia, a multimatched recipients treated with an additional agent (p > 0.05). The level of sirolimus in groups 9 and 10 was ple linear regression type analysis using indicator variables for the presence or absence of each medication not associated with occurrence of CMV DNAemia (p = 0.99).
was performed (see Materials and Methods). Analysis of all log-transformed CMV DNAemia data (n = 706) Time of Onset and Intensity of CMV DNAemia Level resulted in the following equation, which incorporates only the statistically significant contributions (i.e., only Data regarding time of onset for all animals that tested positive is shown in Figure 1C . For 6/7 SFISthose treatments that had a statistically significant nonzero contribution in increasing DNAemia intensity): treated, CMV positive animals, CMV DNAemia was detected in blood after the first month posttransplant (POD log e (CMV DNA + 1) = + 0.375 ±0.046 I TMG/FLUD + 0.271 ±0.087 38-256), but onset was much earlier for other treatment I anti-CD40L + 0.155 ±0.041 I Daclizumab groups.
The distributions of intensity and duration of CMV n = 706, r = 0.419, SE = 0.723, F = 49.9 DNAemia in the different treatment groups are summarized in Table 2 . CMV levels and duration varied among This indicates that animals receiving thymoglubolin ± fludarabine had, on average, an increase in their DNAemia individual animals even within the same treatment group. Animals that had received thymoglobulin alone of 0.45 copies/ng DNA (e 0.375 − 1 = 0.45) (despite many of them receiving effective ganciclovir therapy) (p = 2.5 × or together with fludarabine induction therapy had a significantly higher average intensity (4.02 ± 1.75 vs. 0.19 ± 10
) and those receiving daclizumab had an average increase of 0.17 copies/ng DNA (p = 0.0002). Those re-0.10 copies/ng DNA; p < 0.05) and longer duration (23.0 ± 5.3 vs. 0.5 ± 0.3 days; p < 0.001) of CMV ceiving anti-CD40L had an average increase of 0.31 (p = 0.002); however, the group receiving anti-CD40L alone DNAemia compared to those animals that did not receive thymoglobulin and fludarabine (Fig. 1D) . As a (group 7, n = 3) showed no DNAemia. composite measure of severity and duration, an AUC Donor Tissues and CMV DNAemia type descriptor was calculated. This also showed a very clear difference between the thymoglobulin ± fludaraBefore transplantation, all donors were CMV negative in peripheral blood. The effect of donor islets on bine group and the rest of the animals (367.0 ± 121.1 vs. 75.4 ± 40.2 days × copies/ng DNA; p < 0.05); a correthe occurrence of CMV DNAemia was examined in recipients that received only islets and no bone marrow sponding comparison for all groups is shown in Figure 1E . + were above the respective levels (Fig. 3) . only one pair was positive for CMV DNA in both treated and control animals. The rest occurred randomly Effectiveness of Valganciclovir on Prevention among different recipients. To assess the effect of donor of CMV DNAemia bone marrow, we compared CMV DNAemia in groups 6 and 7 ( Table 1) . Animals in both groups were under Valganciclovir prophylaxis (20 or 10 mg/kg) with induction immunosuppressants did not consistently preanti-CD40L protocol and received multiple doses of bone marrow infusions between PODs −1 and 28, but vent the occurrence of CMV DNAemia in monkeys that received thymoglobulin alone or together with fludarawith different immunosuppressive treatments. All five animals that received thymoglobulin and fludarabine bine. In fact, the aforementioned regression analyses suggested no preventive effect for this treatment (data (group 6) experienced CMV DNAemia, as opposed to none of the three animals that received other immunonot shown). IV infusion of ganciclovir was effective in reducing or eliminating CMV DNAemia in all treated suppressive treatment in group 7.
animals; the average slope calculated for the periods im-
Effect of WBC, Lymphocyte, T-and B-Cell Counts
mediately surrounding the duration of IV ganciclovir on Incidence of CMV DNAemia treatments was −1.68 copies/ng DNA/day for the total of 10 treatments in 7 different animals.
Decreased levels of WBC, and T and B cells were highly associated with the occurrence of CMV DNAemia
Recurrence of CMV DNAemia in transplanted animals. In animals receiving thymoglobulin ± fludarabine, the WBC, lymphocyte, and T-cell Recurrence of CMV DNAemia was found in 18 out of 27. Most of the animals (14/18) were receiving oral nadirs occurred within a week before or after islet transplant, with reductions of WBC, lymphocyte, total CD3 + , valganciclovir therapy, but none were on IV ganciclovir therapy at the time of recurrence. Average intensities CD3 +
CD4
+ , and CD3 + CD8 + subsets greater than 77%, 93%, 95%, 97%, and 95%, respectively, compared to between the recurrent and initial CMV DNAemia were similar (7.3 ± 2.3 vs. 7.1 ± 1.5 copies/ng DNA), but dupreimmunosuppression levels (Table 3) . CMV DNAemia (75-100%) occurred 1-3 weeks later. B-cell reduction rations were much shorter in the recurrent CMV DNAemia than in the initial onset (3.1 ± 0.7 vs. 23.3 ± 6.1 days). ranged from 84% to 94% and occurred within the first 2 months posttransplant. Although not as dramatic as the CMV DNAemia and CMV Disease aforementioned data, SFIS-treated animals also experienced reduction of WBC and lymphocytes, and onset of Six animals showed clinical evidence of CMV disease posttransplant. Two of these animals each were CMV DNAemia occurred later, with a reduced intensity of disease. Figure 2A shows the relationship between from groups 6, 8, and 10 ( Table 1) . Common clinical signs included weight loss, anorexia, soft feces, and leth-CMV DNA levels and WBC, lymphocyte counts posttransplant in three animals in the Sm-Lex protocol. Figargy . Laboratory abnormalities included increased liver enzymes (AST), thrombocytopenia, and occasionally ure 2B shows CMV DNAemia in relation to the levels of CD3
+ CD4 + , CD3 + CD8 + , and CD20 + lymphopancytopenia (data not shown). Of the six animals that died or were euthanatized from overt CMV disease, cyte subsets in different treatment groups. The nadirs of WBC, lymphocytes, T and B cells for animals that three received IV ganciclovir therapy for 7-14 days. These animals experienced a decrease in the level of developed CMV DNAemia within the next 3 weeks were all significantly lower than the respective levels for CMV DNAemia; however, they invariably had a recurrence after IV therapy was discontinued. Oral valgananimals without CMV DNAemia (p < 0.05). We observed that 66.7% of animals with a lowest WBC level ciclovir was given to four animals, and a therapeutic benefit was not seen. The incidence of CMV disease in less than 4,500 cells/µl and 55.2% of animals with a lowest value of lymphocyte less than 1,800 cells/µl deanimals that received thymoglobulin ± fludarabine was 19%, whereas it was 7.7% in the animals without thyveloped CMV DNAemia within the 3 weeks after the nadir; while no animal with a lowest WBC level greater moglobulin ± fludarabine therapy. than 4,500 cells/µl or with a lowest lymphocyte count CMV Distribution in Postmortem Tissues greater than 1,800 cells/µl developed CMV within the next 3 weeks (Fig. 3) . When the lowest levels of CD3 + , Table 4 shows CMV DNA levels in different tissues for all animals that had at least one positive tissue. In CD3
+ , or CD20 + were less than 300, Data was presented as mean ± SD. RD%: reduction % that was calculated against the levels before immunosuppressive treatments. *Data for CD3
, and CD20 + in groups 5, 9, and 10 were from only one animal. , and CD20 + (n = 26) criteria used to separate animals with respective lowest level, below or above selected criteria (lymphocyte data was obtained after omission of one animal that developed CMV within 3 weeks despite a lowest lymphocyte level of 4028 cells/µl). the animals diagnosed with CMV disease, the tissues routes as in humans. CMV infection is asymptomatic in immunocompetent NHP (52); however, just as in human most frequently positive for CMV DNA were kidneys and heart (6/6), followed by lung and liver (4/5), spleen transplants (8, 28) , in immunosuppressed NHP recipients after organ transplantation CMV infection can be reactiand mesenteric lymph nodes (4/6), jejunum (3/6), stomach, duodenum, and inguinal lymph nodes (2/5), and ilvated and lead to CMV disease, which can be life threatening. CMV reactivation has been reported in cynomoleum (2/6). When an animal was severely infected with CMV, all the tissues tested were positive as is shown gus (29, 35) and rhesus (1, 12, 44) monkeys and baboons (40) after organ transplantation. Immunosuppressive for animal 13-1005. In the animals with positive CMV DNA, but no CMV disease (animal #93-353, 111X, regimen used in transplantation has a major impact on the frequency and severity of CMV reactivation. In this 124-1349), kidney and mesenteric lymph nodes were CMV positive. Pancreas and spleen were CMV positive study, we demonstrate that CMV DNAemia not only occurred more frequently and earlier, but was also more in one of the three animals, and all other tissues tested were CMV negative.
severe in islet cell transplanted cynomolgus monkeys that had received thymoglobulin alone or together with fludarabine. CMV DNAemia in thymoglobulin-alone DISCUSSION animals was slightly, but not significantly, lower than in animals treated with both thymoglobulin and fludaraSimilar to CMV infection in humans, CMV is ubiquitous in NHP populations (5) . Of the many CMV strains bine. The appearance of CMV DNAemia within the first month posttransplant in animals receiving thymogloisolated from numerous species of NHP, rhesus CMV (RhCMV), isolated from rhesus macaques, is the best bulin induction therapy with or without fludarabine may be a consequence of extensive WBC and lymphocyte characterized. It has been reported that almost all the rhesus macaques, whether in the wild or in captivity, are depletion. CMV DNAemia occurred after POD 60 in most of the animals with other induction treatments. Deseropositive by 1 year of age (5, 57) . Seropositive animals persistently secret infectious virus during their lifespite the limited number of animals included in each group in the study, these findings have potential reletime (4, 33) , and CMV is probably transmitted from infected to uninfected animals via excretion of virus in vance in CMV prevention in cell transplantation in NHP as described below. breast milk, saliva, and urine (2), the same transmission Higher CMV incidence and infection was reported intravenous administration of medication is much more difficult in NHP than in clinical patients. Oral medicacoincided with a significant reduction of CD3 + and CD4 + cells in AIDS patients (21, 47) and in kidney transplant tions must be broken or crushed and added to a palatable treat, such as a Fig Newton cookie , which adds variabilrecipients (15, 18) . In this study we found that the numbers of WBC, lymphocytes, CD3
ity in the amount of drug actually consumed by the animal. and CD20
+ cells were drastically decreased in islet transplanted NHP after thymoglobulin treatment, with an Donor tissues, islets, and/or bone marrow did not appear to affect CMV DNAemia in transplanted recipients. even greater reduction in lymphocyte, T and B cells when combined thymoglobulin/fludarabine therapy was This was clearly observed in pairs of recipients that received the same amount of islets from the same donor used. Levels of WBC, lymphocytes, T and B cells were highly associated with the frequency, intensity, and duunder the same immune suppression, and one animal received the experimental agent, while the other served as ration of CMV DNAemia in the transplanted animals. The value of WBC, T and B cells at the nadir of cell control. In only 1/9 pairs of such animals both experimental and control recipients developed CMV DNAemia, depletion greatly affect the occurrence of CMV DNAemia. We found that no animals developed CMV DNAemia while CMV DNAemia in the rest of the recipients occurred randomly. In addition, in recipients of several with the next 3 weeks when the lowest value of WBC, lymphocyte, CD3
+ doses of bone marrow under a similar protocol, only those animals that received thymoglobulin and fludaracells was above 4500, 1800, 300, 200, 150, or 300 cells/ µl, respectively. To our knowledge, this is the first time bine developed CMV DNAemia. No correlation was observed between the occurrence that threshold levels of WBC, lymphocyte, T and B cells for CMV infection in immunosuppressed transplanted of CMV DNAemia and the decrease in graft function (assessed by the c-peptide value within 3 weeks of ocanimals are reported. These threshold levels should serve as a guideline for transplanted animals undergoing currence of CMV DNAemia) in the studied monkeys (data not shown). However, CMV infection had a signifimmunosuppressive protocols.
In monkeys that had undergone SFIS therapy, the inicant negative impact on the survival of transplanted animals. Six recipients had poor appetite, diarrhea, and cidence of CMV DNAemia was much lower. These results are in agreement with previous findings from our weight loss in association with CMV disease and expired or had to be euthanatized. Clinical Islet Transplant Program; only one recipient with CMV disease was observed despite CMV positive
In conclusion, the prevalence of CMV infection in animals treated with SFIS was significantly lower than donors and negative recipients (n = 29 patients) (16, 24) .
In humans, administration of antiviral prophylaxis in animals treated with thymoglobulin ± fludarabine. Induction treatment with thymoglobulin and fludarabine during the first 3 months following solid organ transplantation has been shown to have a significant impact significantly increased the frequency, intensity, and duration of CMV infection with drastic reduction of WBC, on the frequency, timing, and outcome of CMV infection and disease (13,32,42,51). Both preemptive valganlymphocytes, CD3 + , CD3 + CD4 + , CD3 + CD8 + , and CD20 + cells. Even though the effect of the use of thymoglobulin ciclovir therapy and valganciclovir prophylaxis were found equally effective in the prevention of CMV disin CMV reactivation and disease in clinical transplantation has been reported before, here, for the first time, we ease after renal transplantation (45) . However, two cases of CMV infection and one case of CMV disease were show the levels of WBC, T and B cell above which there is a minimum risk of CMV infection in NHP recipients reported during the 3-month period of ongoing CMV prophylaxis with oral valganciclovir posttransplant in isof islet cell transplants under various immunosuppressive protocols. One of the significant points of this study let transplantation, in which induction therapy with antithymocyte globulin was used (59). Prophylactic ganis that when testing novel immunosuppressants that may cause drastic reductions in WBC, T and B cells in NHP, ciclovir (2.5 mg/kg/day, intramuscular) treatment was used in immunosuppressed cynomolgus macaque recipiprophylactic CMV treatment of recipients with ganciclovir (IV or IM) should be used, together with a close ents of porcine islets (30) or embryonic pig pancreatic tissue (29) . However, even under ganciclovir prophymonitoring of WBC, T and B cell, and CMV levels, especially within the first month posttransplant. Oral laxis, CMV reactivation was reported in one fourth of animals that received thymoglobulin induction treatment valgancyclovir prophylaxis cannot prevent CMV infection in this large-animal model. Therefore, once CMV (29) . In our study in cynomolgus monkeys, oral valganciclovir prophylaxis did not consistently prevent the onDNAemia is detected, IV ganciclovir should be administered immediately to prevent the development of CMV set of CMV DNAemia and CMV disease; however, treatment of animals with newly detected CMV DNAemia disease. (IV ganciclovir) was effective in reducing or eliminating 
